<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01660308</url>
  </required_header>
  <id_info>
    <org_study_id>201105045RC</org_study_id>
    <nct_id>NCT01660308</nct_id>
  </id_info>
  <brief_title>Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia</brief_title>
  <official_title>Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibroblast froth factors (FGFs) are humoral factors identified by their ability to stimulate&#xD;
      cell proliferation1. They play different roles in the regulation of cell proliferation,&#xD;
      differentiation and function. Most FGF family members act as paracrine factors. But&#xD;
      FGF19(FGF19) subfamily members, including FGF19, 21, and 23, work as endocrine factors to&#xD;
      regulate bile acid, carbohydrate and phosphate metabolism2. Of these, FGF23 plays an&#xD;
      important role in phosphate and bone metabolism3. FGF23 gene encodes 251 amino acids,&#xD;
      including a 24-amino acid signal peptide4. The secreted FGF23 is a protein consisted of 227&#xD;
      amino acids. It works by binding to a Klotho-FGF receptor 1c (FGF1c) complex5. FGF suppresses&#xD;
      the expression of type 2a and 2c sodium-phosphate cotransporters, which mediate phosphate&#xD;
      reabsorption in proximal tubules.6 FGF23 decreases 25-hydroxyvitamin D-1α-hydroxylase&#xD;
      expression and enhances 25-hydroxyvitamin D-24-hydroxylase expression6. Therefore, FGF23&#xD;
      reduces serum 1,25-dihydroxyvitamin D〔1,25(OH)2D〕, which stimulates intestinal calcium and&#xD;
      phosphate absorption. FGF23 decreases serum phosphate through the above mechanisms FGF23&#xD;
      over-expression might result in hypophosphatemic rickets and osteomalacia.&#xD;
&#xD;
      Tumor induced osteomalacia (TIO) is a paraneoplastic syndrome usually caused by benign&#xD;
      phosphaturic mesenchymal tumors. Symptoms are nonspecific, such as general weakness, fatigue,&#xD;
      and bone pain. Sometimes fracture may occurs. The responsible tumors are sometimes small and&#xD;
      difficult to detect. Tumors secrete FGF23. FGF23 reduced phosphate reabsorption in the&#xD;
      proximal tubules and decrease 1,25(OH)2D levels, which result in hypophosphatemia and then&#xD;
      osteomalacia.&#xD;
&#xD;
      The investigators would like to observe the changes of FGF23 in patients who receive&#xD;
      operation or medical treatment and hope this will benefit future treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>FGF23, P</measure>
    <time_frame>at the time TIO is diagnosed</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hypophosphatemia</condition>
  <arm_group>
    <arm_group_label>Tumor induced osteomalcia</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with tumor induced osteomalacia and people without osteomalacia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with tumor induced osteomalacia.&#xD;
&#xD;
          -  people without osteomalacia such as healthy people,&#xD;
&#xD;
          -  people under dialysis,&#xD;
&#xD;
          -  people with poor nutrition.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  people younger than 20 years old or older than 85 years old.&#xD;
&#xD;
          -  people who are pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shyang-Rong Shih, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shyang-Rong Shih, PhD</last_name>
    <email>srshih@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shyang-Rong Shih, PhD</last_name>
      <phone>886-972653337</phone>
      <email>srshih@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Shyang-Rong Shih, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>August 5, 2012</study_first_submitted>
  <study_first_submitted_qc>August 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2012</study_first_posted>
  <last_update_submitted>July 4, 2016</last_update_submitted>
  <last_update_submitted_qc>July 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteomalacia</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

